Quoin Pharmaceuticals Reports Positive Interim Data From Ongoing Phase 2/3 Study Of Qrx003 In Netherton Syndrome

Aug. 28 (Reuters) - Quoin Pharmaceuticals Ltd said interim data from its ongoing phase 2/3 study of Qrx003 in Netherton syndrome were positive.

• The company expects to complete recruitment by the end of 2026 and report topline data in Q2 2027.
• No treatment-related serious adverse events or clinically significant abnormalities were reported.
• 66.7% of participants achieved a 1-grade or greater IGA improvement at week 12.
• The key secondary endpoint of Global Impression of Change achieved statistical significance at week 12.
• Quoin Pharmaceuticals Ltd said it expects to report topline data in Q2 2027 for the study of Qrx003 in Netherton syndrome.